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Although current chemotherapy regimens are effective at
eliminating the bulk of acute myeloid leukemia (AML) blasts,
the disease relapses in the majority of patients.
1 Whether relapse
arises through the selection of a relatively rare subpopulation of
cells present at diagnosis having speciﬁc characteristics that
facilitate chemoresistance or through the induction of changes
required to render them resistant to the chemotherapy is
uncertain. Identiﬁcation of the characteristics that confer
chemoresistance, whether selected or induced, would allow
for the implementation of additional therapies that target the
lynchpin of resistance, thus improving disease outcome.
This study evaluated whether single-cell network proﬁling
(SCNP), a process that simultaneously measures post-transla-
tional protein modiﬁcations (for example, phosphorylation,
acetylation and so on) in multiple signaling pathways within a
single cell, could be used to functionally characterize intra-
cellular pathways associated with in vivo AML chemotherapy
resistance.
2,3 Speciﬁcally, we hypothesized that leukemic blasts
at relapse have different signaling characteristics from those at
diagnosis and that assessing intracellular signaling networks
Table 1 Clinical characteristics of patient donors for longitudinally paired diagnosis and relapse samples
Donor Age
(years)
Gender Sample
source
Secondary
AML
FAB Cytogenetics Cytogenetic
group
FLT3-
ITD
Induction
chemotherapy
Induction
response
Relapse CR
duration
(weeks)
1 77.8 M BM No M0 46,XY,t(3;21)
(q26;q22)
Unfavorable Neg IDA+HDAC CR Yes 46.143
2 34.8 F BM No M2 t(6;9) Unfavorable Pos IA+ZARNESTRA
a CR Yes 11.143
Abbreviations: BM, bone marrow; CR, complete response; F, female; FAB, French-American-British classiﬁcation system; FLT3-ITD, FMS-like
tyrosine kinase 3 receptor (FLT3) internal tandem duplications (ITD); HDAC, high-dose Ara-C; IDA, idarubicin; M, male; Neg, negative;
Pos, positive.
aIDA+Ara-C+Zarnestra.
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Figure 1 Study schema. The two-step process involves the identiﬁcation of resistance-associated signaling node subpopulations followed by
testing the predictive value of these proﬁles for disease response in an independent data set. The top portion of the diagram shows a time
continuum of AML therapy, with A and B representing the time points (diagnosis and ﬁrst relapse after complete response (CR) when samples were
collected on the two patients for SCNP analysis). The signaling modulators, readouts, drug transporters and chemokine receptor tested are listed.
The lower portion of the schema depicts the application of the chemoresistant proﬁles to an independent data set of 47 patients. CR, complete
response; G-CSF, granulocyte colony-stimulating factor; IL-27, interleukin-27; Rx, therapy.
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the same patient) AML bone marrow (BM) samples at diagnosis
and relapse time points may enable functional characterization
of the mechanisms of chemoresistance in cell subpopulations
that are dominant at relapse. The above hypothesis was tested
by searching for resistance-associated signaling nodes in paired
diagnosis/relapse samples from two AML patients and then
examining the predictive value of the identiﬁed resistance-
associated signaling nodes in an independent set of diagnostic
AML samples collected from patients that had a complete
disease response
4 to standard induction chemotherapy and for
which clinical annotation about disease relapse was available.
Clinical characteristics of the two AML patients are shown
in Table 1. Both patients received high-dose cytarabine-
based induction chemotherapy with complete disease response
followed by relapse within 1 year. Cytogenetic analysis
revealed prognostically unfavorable translocations of AML1-
EVI1 and DEK-NUP214 [t(6;9)] in patients 1 and 2, respectively.
In addition, patient 2 had FMS-like tyrosine kinase 3 receptor
internal tandem duplications (FLT3-ITD)-positive leukemia, a
known poor prognostic marker for relapse risk and overall
survival and associated with the DEK-NUP214 translocation in
the majority of cases.
5 Healthy control BM mononuclear cells
(N¼2) were derived from young healthy male volunteers
(age¼18 and 20 years, respectively).
The cryopreserved BM samples from the above two AML
patients were processed (thawed, modulated, ﬁxed, permeabilized
and incubated with antibodies to both surface and intracellular
proteins)
2,3,6 to assess whether speciﬁc cell subpopulations
identiﬁed using cell surface phenotypes and/or signaling proﬁles
were present in the relapsed sample in a greater percentage than
observed in the corresponding diagnostic sample (Figure 1). Next,
in an independent and larger group of diagnostic patient samples,
blasts with the previously identiﬁed cell proﬁles were examined
for their association with disease relapse (Figure 1).
The two longitudinally paired samples were ﬁrst compared
for expression of conventional surface markers used to deﬁne
myeloblast maturity as shown in Figure 2a.
7 Cell subpopulations
Figure 2 (a) Gating analysis to deﬁne leukemic blast population. Flow cytometry plots and sequential gating scheme. The ﬁrst panel is a ﬂow
cytometry dot plot indicating how non-cellular debris was excluded using an FSC and SSC gate (R1). The second panel is a ﬂow cytometry dot plot
indicating how non-viable cells were excluded and viable cells included with an SSC and Aqua viability dye gate (R2). This gating scheme ensured
that only live cells were analyzed for signaling responses. The third panel is a ﬂow cytometry dot plot indicating CD45þ cells (R6) that were then
subdivided into groups of immature CD34þ CD11b  (R1&R2&R6&R4), mature CD33þ CD11bþ (R1&R2&R6&R5) and intermediate
(R1&R2&R6 NOT R4 &R5) myeloid leukemic blasts. (b) Cell surface markers did not identify resistance-associated myeloblast subpopulations.
Shown are bar graphs that depict the percentage (of total blasts) of immature, intermediate and mature blasts (as deﬁned above in a) found in the
diagnosis and relapse samples from patient 1 (top panels) and patient 2 (bottom panels).
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informative of relapse risk for either patient sample (Figure 2b).
Examination of intracellular signaling proﬁles revealed
functionally distinct cell subsets in the otherwise phenotypically
similar relapse and diagnosis samples (Figure 3 and Supple-
mentary Figure 1). Speciﬁcally, when the relapse samples from
patient 1 and patient 2 were modulated using stem cell factor
(SCF), both p-Akt and p-S6 were induced in 3.2 and 31.7% of
cells, respectively (Figure 3). A similar ﬁnding of an increased
percentage of myeloblast subpopulations deﬁned by intra-
cellular signaling proﬁles in relapse versus diagnosis samples
was observed when FLT3L (inducing p-S6 and p-Akt, Figure 3)
and interleukin-27 or granulocyte colony-stimulating factor
(inducing p-signal transducer and activator of transcription
(STAT)3 and p-STAT5) were used as modulators (Supplementary
Figure 1).
To investigate whether similar cells were present at the time of
diagnosis, which would support the concept of selection, or
absent, supporting the idea of an induced change, we looked for
the presence of cells with similar functional responses to SCF,
FLT3L, interleukin-27 and granulocyte colony-stimulating factor
in the corresponding diagnosis samples. While no interleukin-
27-responsive subpopulation was identiﬁed, SCF-, FLT3L- and
granulocyte colony-stimulating factor-responsive cells were
observed in the diagnostic AML BM samples (Figure 3 and
Supplementary Figure 1), although in a lower percentage
(B1%). SCF-responsive cells, deﬁned by the SCF:p-Akt/p-S6
signaling proﬁle, were phenotypically diverse in the relapse
AML samples compared with SCF-responsive cells in healthy
donor BM samples (Figure 4). In healthy BM samples, the SCF:
p-Akt/p-S6 proﬁle existed speciﬁcally in a subset of progenitor
cells with the CD34þ, CD33 , CD11b  phenotype (Figure 4).
After identifying the resistance-associated signaling nodes in
the relapsed samples, we hypothesized that detection of the
same nodes in the diagnostic samples might be predictive of
poor outcome (early relapse). We ﬁrst applied the SCF:p-Akt/
p-S6 gating scheme (as deﬁned in Supplementary Figure 2) to
an independent set of diagnostic AML samples. The clinical
characteristics of these 47 patients are shown in Table 2. All
patients received high-dose cytarabine-based induction chemo-
therapy with disease response of complete remission. Of these,
27 experienced disease relapse (complete response followed by
relapse, CR Rel), while 20 remained in complete continuous
remission for two or more years. Patients from whom this
independent sample set was obtained were young (41/47; o60)
and a high proportion (20/47) had French-American-British
classiﬁcation system M2 AML.
In seven diagnostic AML samples, a subset of leukemic blast
cells that responded to SCF modulation by phosphorylation of
p-Akt and p-S6 were observed (Table 2, Supplementary Table
S1). Of those seven, six patients experienced disease relapse
within 2 years (P¼0.21, Fisher’s exact test) from remission,
while the seventh patient had a complete remission lasting more
than 2 years; interestingly, this AML sample had favorable
cytogenetics, t(8;21) (Figure 5 and Supplementary Table S1). Of
note, all of the patients with this SCF-responsive proﬁle were
less than 60 years old and, with the exception mentioned above,
they all had intermediate- or high-risk cytogenetics; six out of
seven also had an early myeloid FAB classiﬁcation of M1 or M2.
Also of note, the occurrence of the SCF:pAkt/pS6 subpopulation
was independent of the presence of FLT3-ITD: only one of the
six samples was positive for FLT3-ITD mutation. Importantly, the
predictive value of the combination of FLT3-ITD and SCF:p-Akt/
p-S6 for disease relapse was greater than that of either biomarker
individually (P¼0.03, Fisher’s exact test, Table 3).
We next examined whether expression of c-Kit, the receptor
for SCF, could function as a surrogate marker for the SCF:p-Akt/
p-S6 phenotype. Although only samples that expressed c-Kit
Figure 3 Examination of signaling proﬁles revealed differences in relapse and diagnosis samples for SCF and FLT3L. (a) Shown are ﬂow cytometry
dot plots measuring phospho-S6 (X-axis) versus phospho-Akt (Y-axis) in response to no modulator/basal, modulation with SCF or modulation with
FLT3L for patient 1 (left side) and patient 2 (right side) leukemia samples at diagnosis (top panels) and at ﬁrst relapse after complete remission
(lower panels). (b) Figure showing the percentage of cells positive for both p-Akt and p-S6 in diagnostic and relapse samples.
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expression levels and likelihood of leukemia relapse (Figure 6a)
was observed, suggesting that c-Kit expression is a necessary but
not sufﬁcient condition for SCF-induced intracellular signaling.
In line with this observation, the removal of non-c-Kit-
expressing samples improved relapse prediction (Figure 6b).
Furthermore, when blast cells from an AML sample were
simultaneously examined for c-Kit and the downstream signal-
ing marker p-Akt, intra-patient heterogeneity in c-Kit expression
and response to SCF within c-Kit-expressing cells were observed
(Figure 6c).
We also examined whether FLT3L:p-Akt/p-S6, granulocyte
colony-stimulating factor:p-STAT3/5 or interleukin-27:p-STAT3/
5 signaling nodes predicted poor outcome in the same
independent set of diagnostic AML samples. Unlike SCF:p-Akt/
p-S6 gate, no association was found with disease relapse
(Supplementary Table S2).
Relapse due to chemoresistant residual disease is a major
cause of death in both adult and pediatric patients with AML,
and aberrant signal transduction within pathways that control
cell proliferation and survival is thought to have an important
role in secondary chemoresistance. In this study, we used SCNP
as a strategy to identify speciﬁc signaling pathway proﬁles
associated with in vivo chemoresistance using paired diagnosis
and relapse samples. Although it was performed on a limited
number of paired AML samples, our study provides unique
insights into the nature of AML secondary chemoresistance in
rare cell populations, identifying a functionally characterized
cell subset associated with likelihood of early relapse when the
assay was applied in a separate patient cohort.
A subset of leukemia cells with enhanced activity within the
phosphoinositide 3-kinase/Akt cascade (SCF:p-Akt/p-S6) was
found to be commonly expanded in the two leukemia samples
collected at relapse. Importantly, the presence of cell sub-
populations expressing this same signaling proﬁle at diagnosis
was associated with disease relapse after complete response to
induction chemotherapy in an independent sample set of AML
diagnostic samples. Although the SCF:p-Akt/p-S6 proﬁle was not
present in all patients with relapsed disease, all but one patient
with a diagnostic sample containing a subpopulation of X3%
Figure 4 In the relapse samples, the SCF:p-Akt/p-S6 signaling proﬁle is present in a small subset of AML cells that are phenotypically diverse.
Myeloid cells (R1&R2&R6 gatedFsee Figure 2a) are displayed on a three-parameter plot with three ﬂuorescent cell surface markers: CD11b
(X-axis), CD33 (Y-axis) and CD34 (Z-axis). Red spheres are cells that stain positive for the SCF:p-Akt/p-S6 signaling proﬁle. Bone marrow cells from
a representative healthy individual (bottom right) show that normally the SCF:p-Akt/p-S6 proﬁle exists mostly in a subset of progenitor cells with the
CD34þ, CD33 , CD11b  phenotype. To the right of each plot are box and whisker plots that show the relative expression (log10 ﬂuorescence) of
CD34 in the SCF:p-Akt/p-S6-responsive and non-responsive populations for two relapse AML samples and one healthy sample. In the box and
whisker plots, boxes contain 50% of the sample data with the median values indicated by a horizontal bar. Whiskers contain 1.5  the
interquartile range and outliers past this range are shown as individual points.
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data support the marked biological heterogeneity at the
basis of AML secondary chemoresistance and lend merit to
the approach of studying signaling proﬁles in functionally
distinct subpopulations in longitudinally collected AML samples
before and after therapy to identify poor-prognostic cell
populations.
Currently there are no measures to indicate why patients
with similar clinically appearing disease have different
responses to therapy, with some remaining disease free while
others undergo disease relapse and ultimately succumb. SCNP
permits an accurate characterization of each individual’s
leukemia signaling pathway phenotype and biological hetero-
geneity, allowing for a more efﬁcient delineation of the
normality or pathology of leukemic subpopulations. This study
shows that leukemic cell populations differ quantitatively
and qualitatively before and after in-vivo therapeutic pressure
in AML, and that SCNP offers a novel approach to identify
chemotherapy-resistant subpopulations that may predispose
patients to disease relapse.
Table 2 Clinical characteristics of independent test set of 47 patient samples
Characteristic Total 40 non-SCF responsive 7 SCF responsive
Total samples¼47 CCR CR Rel CCR CR Rel
CCR 20 (74%) 19 1
CR Rel 27 (26%) 21 6
Age
o60 years 41 (87%) 17 17 1 6
460 years 6 (13%) 2 4 0 0
Cytogenetics
Favorable 6 (12.7%) 4 1 1 0
Intermediate 24 (51%) 11 9 0 4
Unfavorable 17 (29.7%) 4 11 0 2
FAB
M0 1 0 1 0 0
M1 7 1 2 0 4
M2 20 10 8 1 1
M4 10 5 5 0 0
M4EOS 1 1 0 0 0
M5 (A,B,C) 5 2 3 0 0
M6 1 0 0 0 1
Unknown 2 0 2 0 0
FLT3 mutation
ITD 10 (21.3%) 2 7 0 1
WT 35 (74.5%) 16 13 1 5
Unknown 2 (4.2%) 1 1 0 0
Abbreviations: CCR, complete continuous remission; CR, complete response; CR Rel, complete response followed by relapse; SCF, stem cell
factor; WT, wild type.
Table 3 The SCF: pAkt/pS6 proﬁle is independent of FLT3-ITD
status
SCF non-responsive
and FLT3-WT
SCF responsive
or FLT3-ITD
CCR 17 3
CR Rel 14 13
Fisher’s test P¼0.03
Abbreviations: CCR, complete continuous remission; CR, complete
response; SCF, stem cell factor; WT, wild type.
Figure 5 Application of SCF:p-Akt/p-S6 gate identiﬁes a subset of
patients with relapsed disease. Shown are box and whisker plots of
patients with leukemia that relapsed within 2 years (complete response
(CR) Rel, right side) versus those in complete continuous remission for
2 or more years (CCR, left side) and the percentage of SCF-responsive
(inducing p-S6 and p-Akt) blasts. To the right of the plots each symbol
represents an individual sample. A circle is drawn around the six
patient samples whose diagnostic samples showed X3% of SCF:p-Akt/
p-S6 cells and who experienced disease relapse. The cytogenetics of
the CCR sample with the SCF-responsive subpopulation is depicted.
Note: In box and whisker plots, boxes contain 50% of the sample data,
with the median values indicated by a horizontal bar. Whiskers
contain 1.5  the interquartile range and outliers past this range are
shown as individual points.
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Figure 6 (a) c-Kit (SCF receptor) expression is not predictive of SCF responsiveness. Shown are box and whisker plots of patients with leukemia
that relapsed within 2 years (complete response (CR) Rel, right side) versus those in complete continuous remission for 2 or more years (CCR, left
side) and the percentage of cells with c-Kit surface expression. To the right of the plots each symbol represents an individual sample. Note: In box
and whisker plots, boxes contain 50% of the sample data, with the median values indicated by a horizontal bar. Whiskers contain 1.5  the
interquartile range and outliers past this range are shown as individual points. (b) Only samples that expressed c-Kit were able to respond to SCF.
Scatter plot of SCF-responsive SCF-p-Akt/p-S6 (X-axis) and percent-positive cells for c-Kit (Y-axis) for relapsed samples (circles) and CCR samples
(pluses). (c) Simultaneous staining of c-Kit and p-Akt shows multiple c-Kitþ cell subsets that vary in p-Akt signaling in response to SCF. Phospho-
Akt versus c-Kit 2-D contour plots with and without SCF for 15-min incubation. Quadrant gate was applied based on the isotype controls.
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